Omicron variant evades Covid19 inactivated vaccine, Nature published study says. “Third shot of another type of RNA or purified proteins vaccine offer better protection”

London, 15 Jan 2022 – A study published on Nature on 13 Jan. 2022, shows Omicron Covid variant evades Covid19 inactivated vaccine (like Covavac/Sinovac, Sinopharm, Covaxxin or VLA2001). The result of the study is based on “laboratory evidence”.  

“The findings – says the publication – are prompting many scientists and public-health researchers to re-evaluate the role of inactivated vaccines in the global fight against COVID-19”.

“Many people who receive two jabs of an inactivated vaccine fail to produce immune molecules that can counter Omicron transmission”, the study reveals clearing that a third dose with the same kind of inactivated vaccine does not give enough immunity to face Omicron and suggests “a third shot of another type of vaccine, such as those based on messenger RNA or purified proteins, seems to offer better protection against Omicron”.

The study published on Nature relies on multiple sources.

One of them, Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients carried out by teams in School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Princes Department of Pathology and Microbiology of Princess Margaret Hospital Hong Kong, published last 16 December 2021 by by Oxford University Press shows this results:

“The Omicron variant strain HKU344-R346K has an additional spike R346K mutation, which is present in 8.5% of strains deposited in GISAID database. Only 20% and 24% of BNT162b2 (BioNTech, Pfizer vaccine) recipients had detectable neutralizing antibody against the Omicron variant HKU691 and HKU344-R346K, respectively, while none of the Coronavac (inactivated vaccine) recipients had detectable neutralizing antibody titer against either Omicron isolate”. 

The study concludes that: “Omicron variant escapes neutralizing antibodies elicited by BNT162b2 or Coronavac. The additional R346K mutation did not affect the neutralization susceptibility. Our data suggest that the Omicron variant may be associated with lower COVID-19 vaccine effectiveness.